• 06.01.2020 – 10:00

  Kyowa Kirin International PLC

  Kyowa Kirin Announces Marketing Authorisation Application for Istradefylline Validated by European Medicines Agency

  Tokyo (ots/PRNewswire) - Kyowa Kirin Co., Ltd. (TSE: 4151) President and CEO: Masashi Miyamoto, "Kyowa Kirin") today announces that its marketing authorisation application (MAA) for istradefylline (KW-6002) as an adjunctive treatment to levodopa-based regimens in adult patients with Parkinson's disease (PD) ...

  more

• 20.12.2018 – 16:01

  Merck KGaA

  Merck Announces EMA Orphan Drug Designation for Bifunctional Immunotherapy M7824 in Biliary Tract Cancer

  Darmstadt, Germany (ots/PRNewswire) - The information contained is not intended for distribution in the USA, Canada or the UK - European Medicine Agency (EMA) grants M7824, an investigational bifunctional immunotherapy, orphan drug designation in biliary tract cancer (BTC) - EMA orphan drug designation for M7824 in ...

  more

• 20.05.2011 – 16:37

  Astellas Pharma Europe Limited

  Astellas Receives Positive Opinion From CHMP for European Approval of VIBATIV(TM) for Nosocomial Pneumonia Caused by MRSA

  Staines, England (ots/PRNewswire) - Astellas Pharma Europe Ltd., announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion, recommending the granting of marketing authorisation for VIBATIV (telavancin hydrochloride) for the ...

  more